Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2005
No trial phase data available
No trial data available
No trial data available
No approval data available
- NanoViricides' Phase IIA/IIB trial of oral NV-387 gummies for Bundibugyo Ebolavirus is set to start next week at an Ebola treatment center in Ituri province, DRC. - The adaptive trial adds an oral option to the WHO-linked PARTNERS study, which is evaluating infused MBP134 and remdesivir in roughly 300 enrolled patients. - As of September 10, 2026, DRC has reported 7,022 confirmed cases, 3,398 confirmed deaths and 1,671 recoveries, with a crude fatality rate near 48%.
- NanoViricides has filed an Orphan Drug Designation application with the US FDA for NV-387, targeting MPox treatment in a market with no approved therapies. - Current MPox treatments tecovirimat and brincidofovir have demonstrated clinical failures, with tecovirimat showing no effectiveness and brincidofovir causing liver toxicity in patients. - NV-387 has shown strong effectiveness in preclinical orthopoxvirus models and completed Phase I trials with no adverse events, positioning it as a potential breakthrough therapy. - The drug's unique nanomachine mechanism may overcome viral resistance issues that plague existing treatments and vaccines in the rapidly mutating MPox landscape.
- NanoViricides submitted an Orphan Drug Designation application to the FDA for NV-387, a nanomedicine-based treatment for measles, amid rising case numbers in the United States. - The company reported 2,251 measles cases and three deaths in 2025, representing a significant increase from 59 cases in previous years, highlighting the urgent medical need. - If approved, the orphan drug designation would provide NanoViricides with tax credits, fee exemptions, and up to seven years of market exclusivity for NV-387. - The broad-spectrum antiviral NV-387 has demonstrated strong activity in lethal animal models of orthopoxvirus infections, supporting potential applications beyond measles including smallpox and mpox.
- NanoViricides has completed Phase I clinical trials for NV-387, a broad-spectrum antiviral drug, with no reported adverse events or dropouts, demonstrating excellent safety and tolerability in humans. - The company is preparing Phase II clinical trials for NV-387 to treat MPox in Africa and viral respiratory infections, with preliminary approval already obtained from regulatory authorities in the Democratic Republic of Congo. - NV-387 has shown superior efficacy compared to existing antivirals in animal models, outperforming oseltamivir, peramivir, baloxavir for influenza, and remdesivir for COVID-19. - The company projects NV-387 could capture a market exceeding $20 billion if approved for empirical therapy of respiratory viral infections, similar to how broad-spectrum antibiotics are prescribed.
- NanoViricides reports that its broad-spectrum antiviral drug NV-387 could help reduce metastatic cancer resurgence by preventing viral infections from awakening dormant cancer cells. - The drug has completed Phase I clinical trials and is advancing to Phase II, demonstrating effectiveness against multiple respiratory viruses while reducing inflammatory cytokine IL-6 levels. - Recent studies have linked viral infections and increased IL-6 inflammation to higher risk of metastatic cancer resurgence, particularly in COVID-19 and breast cancer patients. - NV-387 outperformed approved antiviral drugs including Tamiflu, Rapivab, and Xofluza in animal studies, showing superior lung protection and anti-inflammatory effects.
- NanoViricides has received approval from the Democratic Republic of Congo's National Ethics Committee to proceed with Phase II clinical trials of NV-387 for MPox treatment, addressing a significant unmet need as no effective treatment currently exists. - NV-387 employs a revolutionary host-mimetic mechanism that "looks like a cell" to viruses, potentially making it effective against 90-95% of human pathogenic viruses while being highly resistant to viral escape mutations. - The drug has demonstrated superior efficacy in animal models against multiple viruses including influenza, RSV, coronavirus, and orthopoxviruses, outperforming existing treatments like Tamiflu, remdesivir, and matching tecovirimat against MPox-like infections.
- NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate, as a potential treatment for measles in response to declining vaccination rates and increasing case numbers across the USA. - The drug candidate has successfully completed Phase I clinical trials with no adverse events reported and has demonstrated efficacy against multiple viruses that utilize the HSPG infection pathway. - NanoViricides is preparing to conduct animal model studies using humanized mice before advancing NV-387 to Phase II human clinical trials, positioning it as a critical treatment option for current and future measles outbreaks.
- NanoViricides has completed Phase I clinical trials for NV-387 with no reported adverse events, demonstrating potential as a broad-spectrum antiviral against MPox, RSV, influenza, and COVID-19. - The company's novel drug candidate NV-387 showed superior efficacy compared to existing treatments for influenza and demonstrated promising results against lethal RSV infections in preclinical studies. - NanoViricides is preparing to advance NV-387 into Phase II trials for multiple indications, including MPox infections and Viral Acute Respiratory Infections, while positioning the drug as a potential countermeasure against emerging H5N1 bird flu threats.
- NanoViricides' NV-387 demonstrated an 88% increase in survival rate in animal studies, surpassing existing treatments for influenza, offering a potential solution against H5N1. - The broad-spectrum antiviral drug candidate mimics essential host-side features, making it difficult for the virus to develop resistance, according to NanoViricides. - Having completed Phase I clinical trials with no adverse events, NV-387 is advancing to Phase II trials for MPox treatment and respiratory virus infections. - NV-387's mechanism targets sulfated proteoglycans, potentially preventing severe pneumonia, and its broad-spectrum activity extends to COVID, RSV, and Orthopoxviruses.
- NanoViricides is set to advance its broad-spectrum antiviral candidate, NV-387, into Phase II clinical trials, focusing on MPox treatment in Central Africa. - NV-387 demonstrated no adverse effects in Phase Ia/Ib trials, paving the way for further clinical development in viral acute respiratory infections and pediatric RSV. - The company is also preparing NV-387 as a countermeasure against the emerging H5N1 bird flu threat, addressing limitations in current vaccines. - NanoViricides has engaged a Clinical Research Organization (CRO) to oversee the Phase II trial for MPox, with trial sites identified in two African countries.
